Teva Pharmaceutical Industries Limited (TEVA) Provides Update on Generic Actonel(R) Litigation
5/13/2009 12:02:27 PM
JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Court of Appeals for the Federal Circuit has affirmed a February 29, 2008 decision by the District Court, which had found Procter & Gamble's U.S. Patent No. 5,538,122 to be valid. As a result of today's decision, Teva expects to market its generic version of Procter & Gamble's Actonel® (Risedronate Sodium) Tablets no later than June 2014, when the patent is otherwise set to expire.